Garry P Duffy

Prof. Garry P Duffy

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2010 in Biomaterials
Verified
Journal Article
Closed access
FLFrank G. Lyons
Frank G. Lyons
AAAmir A. Al-Munajjed
Amir A. Al-Munajjed
SKStephen M. Kieran
Stephen M. Kieran
MTMary E. Toner
Mary E. Toner
Ciara MurphyCiara Murphy
Ciara Murphy
FOFergal J. O’bRien
Fergal J. O’bRien

2 January 2012 in Advanced Materials
Verified
Journal Article
Closed access
PDF file
Caroline M. CurtinCaroline M. Curtin
Caroline M. Curtin
GCGráinne M. Cunniffe
Gráinne M. Cunniffe
FLFrank G. Lyons
Frank G. Lyons
KBKazuhisa Bessho
Kazuhisa Bessho
GDGlenn R. Dickson
Glenn R. Dickson
Fergal O'BrienFergal O'Brien
Fergal O'Brien

1 April 2015 in Advanced Drug Delivery Reviews
Verified
Journal Article
Open access
CHConn L. Hastings
Conn L. Hastings
EREllen Roche
Ellen Roche
EREduardo Ruiz-Hernandez
Eduardo Ruiz-Hernandez
KSKatja Schenke-Layland
Katja Schenke-Layland
CWConor J. Walsh
Conor J. Walsh
GDGarry P Duffy
Garry P Duffy
The spectrum of ischaemic cardiomyopathy, encompassing acute myocardial infarction to congestive heart failure is a significant clinical issue in the modern era. This group of diseases is an enormous source of morbidity and mortality and underlies significant healthcare costs worldwide. Cardiac regenerative therapy, whereby pro-regenerative cells, drugs or growth factors are administered to damaged and ischaemic myocardium has demonstrated significant potential, especially preclinically. While some of these strategies have demonstrated a measure of success in clinical trials, tangible clinical translation has been slow. To date, the majority of clinical studies and a significant number of preclinical studies have utilised relatively simple delivery methods for regenerative therapeutics, such as simple systemic administration or local injection in saline carrier vehicles. Here, we review cardiac regenerative strategies with a particular focus on advanced delivery concepts as a potential means to enhance treatment efficacy and tolerability and ultimately, clinical translation. These include (i) delivery of therapeutic agents in biomaterial carriers, (ii) nanoparticulate encapsulation, (iii) multimodal therapeutic strategies and (iv) localised, minimally invasive delivery via percutaneous transcatheter systems.

13 August 2014 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
PDF file
Caroline M. CurtinCaroline M. Curtin
Caroline M. Curtin
ETErica G. Tierney
Erica G. Tierney
KMKevin McSorley
Kevin McSorley
SCSally-Ann Cryan
Sally-Ann Cryan
GDGarry P Duffy
Garry P Duffy
Fergal O'BrienFergal O'Brien
Fergal O'Brien

1 August 2014 in Biomaterials
Verified
Journal Article
Closed access
EREllen Roche
Ellen Roche
CHConn L. Hastings
Conn L. Hastings
SLSarah A. Lewin
Sarah A. Lewin
DSDmitry E. Shvartsman
Dmitry E. Shvartsman
YBYevgeny Brudno
Yevgeny Brudno
DMDavid J. Mooney
David J. Mooney

1 September 2009 in Tissue Engineering Part A
Verified
Journal Article
Closed access
GDGarry P Duffy
Garry P Duffy
TATabassum Ahsan
Tabassum Ahsan
TOTimothy O’Brien
Timothy O’Brien
FBFrank Barry
Frank Barry
RNRobert M. Nerem
Robert M. Nerem
Bone marrow-derived mesenchymal stem cells (MSCs) have received much attention as a potential treatment for myocardial infarction because of their potential to integrate into the host myocardium and repair the injured heart. The mode of action of stem cell-mediated cardiac repair is still somewhat unclear, including the potential role of MSCs in neovascularization. The objective of this study was to determine the in vitro effect of MSCs on angiogenesis-related endothelial cell (EC) behavior, including migration, monolayer permeability, and vessel formation and stabilization. In a noncontact coculture system, we found that MSCs increase EC proliferation and migration, promoting early events of angiogenesis, while also decreasing EC monolayer permeability. Further, in a time- and dose-dependent manner, MSCs in direct coculture with ECs on Matrigel can increase the persistence of preexisting vessels by greater than threefold, with complex vessels remaining stable for more than 10 days. The results demonstrate that MSCs play an active role in the cellular processes involved in the formation, stabilization, and maturation of newly formed vessels. Further, these outcomes are not governed solely by either paracrine or direct contact effects and are both time and dose dependent.